Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TECLISTAMAB-CQYV Cause Neuropathy peripheral? 36 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 36 reports of Neuropathy peripheral have been filed in association with TECLISTAMAB-CQYV. This represents 2.3% of all adverse event reports for TECLISTAMAB-CQYV.

36
Reports of Neuropathy peripheral with TECLISTAMAB-CQYV
2.3%
of all TECLISTAMAB-CQYV reports
2
Deaths
5
Hospitalizations

How Dangerous Is Neuropathy peripheral From TECLISTAMAB-CQYV?

Of the 36 reports, 2 (5.6%) resulted in death, 5 (13.9%) required hospitalization, and 1 (2.8%) were considered life-threatening.

Is Neuropathy peripheral Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB-CQYV. However, 36 reports have been filed with the FAERS database.

What Other Side Effects Does TECLISTAMAB-CQYV Cause?

Cytokine release syndrome (406) Immune effector cell-associated neurotoxicity syndrome (153) Off label use (122) Death (116) Plasma cell myeloma (96) Infection (83) Neutropenia (74) Fatigue (72) Pyrexia (67) Covid-19 (64)

What Other Drugs Cause Neuropathy peripheral?

LENALIDOMIDE (10,215) BORTEZOMIB (4,067) OXALIPLATIN (3,662) DEXAMETHASONE (3,543) PACLITAXEL (3,508) LEVOFLOXACIN (2,619) CIPROFLOXACIN (2,607) FLUOROURACIL (2,605) CYCLOPHOSPHAMIDE (2,565) POMALIDOMIDE (2,382)

Which TECLISTAMAB-CQYV Alternatives Have Lower Neuropathy peripheral Risk?

TECLISTAMAB-CQYV vs TEDIZOLID TECLISTAMAB-CQYV vs TEDUGLUTIDE TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER TECLISTAMAB-CQYV vs TEGAFUR TECLISTAMAB-CQYV vs TEGAFUR\URACIL

Related Pages

TECLISTAMAB-CQYV Full Profile All Neuropathy peripheral Reports All Drugs Causing Neuropathy peripheral TECLISTAMAB-CQYV Demographics